Scholarlink

<p>The role of T-cell-mediated immune responses is recognized as pivotal in achieving functional cure in chronic hepatitis B (CHB) patients. We aimed to assess safety and T-cell responses induced by JNJ-6430535 (JNJ-0535); a hepatitis B virus (HBV)-specific therapeutic DNA vaccine administered via electroporation-mediated intramuscular injection. JNJ-0535 comprises 2 plasmids, encoding HBV core and polymerase (pol) proteins, respectively. We describe the safety, tolerability, and immunogenicity results of JNJ-0535 from an open-label, single arm phase 1 study in healthy volunteers (HVs) (64300535HPB1003, NTC04736147) and a randomized, placebo controlled phase 1 study in CHB patients (64300535HPB1001, NTC03463369). HBV-specific T-cell responses were evaluated using enzyme-linked immunospot (ELISpot) and intracellular cytokine staining (ICS). We performed baseline single-cell RNA sequencing (scRNA-seq) to explore immune correlates associated with vaccine response in HVs, and baseline serum proteomics (Olink Explore<sup>®</sup> 3072) to explore differences in soluble immune markers between responders and non-responders in both HVs and CHB patients. JNJ-0535 was safe and well tolerated in both HVs and CHB patients. Compared to CHB patients, HVs showed a higher proportion of participants with vaccine-induced HBV-specific T-cell responses (92% versus 50%), a greater increase from baseline (24× [interquartile range=40×;9×] versus 4.8× [interquartile range=5×;6×]) and a broader response in terms of number of antigens. Serum proteomics revealed few differential circulating host biomarkers between CHB and HVs, but these could not be linked to differences in immunogenicity. In addition, whole-blood scRNA-seq was performed in HVs to explore differences between participants with a strong vaccine response and those with low or no response. Our research showed a decrease in vaccine-induced responses in CHB patients compared to HVs and may provide preliminary insights into immune-related biomarkers that could influence vaccine immunogenicity but require further confirmation in future larger studies. <b>trial numbers:</b> 64300535HPB1001 (NCT03463369) First posted: 18. April 2018; ULR: <a href="https://clinicaltrials.gov/study/NCT03463369?term=JNJ-64300535&amp;rank=2">https://clinicaltrials.gov/study/NCT03463369?term=JNJ-64300535&amp;rank=2</a> and 64300535HPB1003 (NCT04736147) First posted: 03. Feb. 2021; URL: <a href="https://clinicaltrials.gov/study/NCT04736147?term=JNJ-64300535&amp;rank=1">https://clinicaltrials.gov/study/NCT04736147?term=JNJ-64300535&amp;rank=1</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety, immunogenicity, and baseline immune correlates of vaccine JNJ-0535 in participants with or without CHB

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月5日

查看全文
  • Simon Verheijden,
  • Nádia Conceição-Neto,
  • Stefan Bourgeois,
  • Céline Vandamme,
  • Ewoud de Troyer,
  • Evangelos Kanoulas,
  • Dries De Maeyer,
  • Marjolein Crabbe,
  • Elli Makariadou,
  • Leen Slaets,
  • Bart Fevery,
  • Pieter Van Remoortere,
  • Michael Biermer,
  • Patrick T. F. Kennedy,
  • An De Creus

摘要

The role of T-cell-mediated immune responses is recognized as pivotal in achieving functional cure in chronic hepatitis B (CHB) patients. We aimed to assess safety and T-cell responses induced by JNJ-6430535 (JNJ-0535); a hepatitis B virus (HBV)-specific therapeutic DNA vaccine administered via electroporation-mediated intramuscular injection. JNJ-0535 comprises 2 plasmids, encoding HBV core and polymerase (pol) proteins, respectively. We describe the safety, tolerability, and immunogenicity results of JNJ-0535 from an open-label, single arm phase 1 study in healthy volunteers (HVs) (64300535HPB1003, NTC04736147) and a randomized, placebo controlled phase 1 study in CHB patients (64300535HPB1001, NTC03463369). HBV-specific T-cell responses were evaluated using enzyme-linked immunospot (ELISpot) and intracellular cytokine staining (ICS). We performed baseline single-cell RNA sequencing (scRNA-seq) to explore immune correlates associated with vaccine response in HVs, and baseline serum proteomics (Olink Explore® 3072) to explore differences in soluble immune markers between responders and non-responders in both HVs and CHB patients. JNJ-0535 was safe and well tolerated in both HVs and CHB patients. Compared to CHB patients, HVs showed a higher proportion of participants with vaccine-induced HBV-specific T-cell responses (92% versus 50%), a greater increase from baseline (24× [interquartile range=40×;9×] versus 4.8× [interquartile range=5×;6×]) and a broader response in terms of number of antigens. Serum proteomics revealed few differential circulating host biomarkers between CHB and HVs, but these could not be linked to differences in immunogenicity. In addition, whole-blood scRNA-seq was performed in HVs to explore differences between participants with a strong vaccine response and those with low or no response. Our research showed a decrease in vaccine-induced responses in CHB patients compared to HVs and may provide preliminary insights into immune-related biomarkers that could influence vaccine immunogenicity but require further confirmation in future larger studies. trial numbers: 64300535HPB1001 (NCT03463369) First posted: 18. April 2018; ULR: https://clinicaltrials.gov/study/NCT03463369?term=JNJ-64300535&rank=2 and 64300535HPB1003 (NCT04736147) First posted: 03. Feb. 2021; URL: https://clinicaltrials.gov/study/NCT04736147?term=JNJ-64300535&rank=1.